Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$9.29 USD
-0.31 (-3.23%)
Updated May 17, 2024 04:00 PM ET
After-Market: $9.30 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TBPH 9.29 -0.31(-3.23%)
Will TBPH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBPH
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Other News for TBPH
Buy Rating Affirmed on Theravance Biopharma Amid Strong Q1 Performance and Promising Pipeline Prospects
Buy Rating Affirmed for Theravance Biopharma on Strong Portfolio Performance and Promising Drug Prospects
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Analysts Have Conflicting Sentiments on These Healthcare Companies: Theravance Biopharma (TBPH), Voyager Therapeutics (VYGR) and Praxis Precision Medicines (PRAX)
TBPH Stock Earnings: Theravance Biopharma Beats EPS, Beats Revenue for Q1 2024